Author pages are created from data sourced from our academic publisher partnerships and public sources.
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1 Diagnosis and Medical Management
This paper is the first in a series of two publications relating to the European Crohn’s and Colitis Organisation [ECCO] evidence-based consensus on the diagnosis and management of Crohn’s disease… Expand
Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.
The treatment of inflammatory bowel disease (IBD) has been revolutionised over the past decade by the increasing use of immunomodulators, mainly azathioprine (AZA)/6-mercaptopurine (6-MP) and… Expand
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.
J.F. Rahier ⁎, S. Ben-Horin, Y. Chowers, C. Conlon, P. De Munter, G. D'Haens, E. Domènech, R. Eliakim, A. Eser, J. Frater, M. Gassull, M. Giladi, A. Kaser, M. Lémann, T. Moreels, A. Moschen, R.… Expand
European evidence based consensus on the diagnosis and management of Crohn’s disease: current management
This second section of the European Crohn’s and Colitis Organisation (ECCO) Consensus on the management of Crohn’s disease concerns treatment of active disease, maintenance of medically induced… Expand
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to…
- G. D'haens, R. Panaccione, +24 authors S. Travis
- The American Journal of Gastroenterology
- 1 February 2011
The advent of biological therapy has revolutionized inflammatory bowel disease (IBD) care. Nonetheless, not all patients require biological therapy. Selection of patients depends on clinical… Expand
Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects.
The first ECCO pathogenesis workshop focused on anti-TNF therapy failures in inflammatory bowel diseases (IBDs). The overall objective was to better understand and explore primary non response and… Expand
Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health
Objective The impact of inflammatory bowel disease (IBD) on disability remains poorly understood. The World Health Organization's integrative model of human functioning and disability in the… Expand
The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab
Objective To characterise the temporal evolution of antibodies to infliximab (ATI). Design Prospective observational study of infliximab-treated patients with inflammatory bowel disease between 2009… Expand
Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima
Objective The cross-immunogenicity of the recently approved infliximab-biosimilar Remsima (CT-P13) with the originator drug Remicade is still unknown. Design Sera of patients with IBD with or without… Expand
Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.
- B. Ungar, Idan Levy, +8 authors S. Ben-Horin
- Clinical gastroenterology and hepatology : the…
- 1 April 2016
BACKGROUND & AIMS It is not clear what serum levels of anti-tumor necrosis factor are associated with reduced intestinal inflammation in patients with inflammatory bowel disease (IBD). We aimed to… Expand